Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial

被引：0
|
作者：
Aixin Shi
Panpan Xie
Lasse Lykke Nielsen
Trine Vang Skjøth
Xuemei He
Sine Pfeiffer Haugaard
机构：
[1] Chinese Academy of Medical Sciences,Clinical Trial Center, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine
[2] Novo Nordisk A/S,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Diabetes; Glucagon-like peptide-1 receptor agonist; Pharmacokinetics; Randomised controlled trial; Semaglutide; Steady state exposure;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：550 / 561
页数：11
相关论文
共 50 条
  • [1] Pharmacokinetics, Safety and Tolerability of Once-Weekly Subcutaneous Semaglutide in Healthy Chinese Subjects: A Double-Blind, Phase 1, Randomized Controlled Trial
    Shi, Aixin
    Xie, Panpan
    Nielsen, Lasse Lykke
    Skjoth, Trine Vang
    He, Xuemei
    Haugaard, Sine Pfeiffer
    ADVANCES IN THERAPY, 2021, 38 (01) : 550 - 561
  • [2] A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects
    Xie, Panpan
    Abildlund, Morten T.
    Baekdal, Tine A.
    He, Xuemei
    Lyauk, Yassine K.
    Patted, Usha Rani H.
    Ning, Zu
    Shi, Aixin
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3068 - 3077
  • [3] A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
    Ikushima, Ippei
    Jensen, Lene
    Flint, Anne
    Nishida, Tomoyuki
    Zacho, Jeppe
    Irie, Shin
    ADVANCES IN THERAPY, 2018, 35 (04) : 531 - 544
  • [4] A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
    Ippei Ikushima
    Lene Jensen
    Anne Flint
    Tomoyuki Nishida
    Jeppe Zacho
    Shin Irie
    Advances in Therapy, 2018, 35 : 531 - 544
  • [5] Safety, tolerability, and pharmacokinetics of ibrexafungerp in healthy Chinese subjects: a randomized, double-blind, placebo-controlled phase 1 trial
    Liu, Xiaoyan
    Zhang, Rui
    Li, Rong
    Wu, Qiong
    Pan, Chao
    Yu, Xiangqing
    Liu, Yuhui
    Wang, Benjie
    Yu, Shuwen
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2023, 67 (12)
  • [6] Tolerability, Safety, and Pharmacokinetics of Once-Weekly Administration of GLP-1 Analogue in Healthy Subjects
    Xu, Michael M.
    DIABETES, 2015, 64 : A72 - A73
  • [7] A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Semaglutide in Healthy Chinese Subjects
    Shi, Aixin
    Xie, Panpan
    Nielsen, Lasse L.
    Skjoeth, Trine V.
    He, Xuemei
    Haugaard, Sine P.
    DIABETES, 2020, 69
  • [8] Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial
    Kita, Toshihiro
    Kaji, Yoshikazu
    Kitamura, Kazuo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 1 - 10
  • [9] Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial
    Vincent, JL
    Spapen, HDMH
    Creteur, J
    Piagnerelli, M
    Hubloue, I
    Diltoer, M
    Roman, A
    Stevens, E
    Vercammen, E
    Beaver, JS
    CRITICAL CARE MEDICINE, 2006, 34 (06) : 1661 - 1667
  • [10] Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase I study
    Huang, Kai
    Ding, Ying
    Que, Linling
    Chu, Nannan
    Shi, Yunfei
    Qian, Zhenzhong
    Qin, Wei
    Chen, Yuanxin
    Gu, Xianghong
    Wang, Jiakun
    Zhang, Zhiwei
    Xu, Jianguo
    He, Qing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345